A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)

Alcoholism Clinical Trial

— APPEAL  

Official title:

A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03060772
• Other study ID #: IRB00071908
• Secondary ID: 1R01AA025857
• Status: Terminated
• Phase: Phase 2
• Start date: January 3, 2018
• Est. completion date: January 28, 2020

Study information

• Verified date: February 2023
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a single center, open-label, randomized clinical trial to determine the effect of pioglitazone (PIO) treatment on alveolar macrophage immune function, redox stress, and NADPH oxidase expression in outpatient alcoholic subjects. The researchers will recruit a cohort of otherwise healthy patients with an alcoholic use disorder from the Substance Abuse Treatment Program at the Atlanta Veterans Affairs (VA) Medical Center and randomize them to receive the usual treatment for two to four weeks or to the usual treatment plus PIO treatment for two to four weeks. There will also be a healthy control group (matched on age, gender, and smoking status) that will receive no treatment. To measure the effect of pioglitazone, participants will undergo a bronchoscopy before taking the study drug and then again 2-4 weeks later to look for changes. The bronchoscopy will allow researchers to obtain fluid from the lungs to see how well their immune cells respond to bacteria by determining phagocytic capacity.

Description:

Alcohol abuse is a major burden on society and an enormous problem in the veteran population. Many people are aware that chronic alcohol ingestion can cause serious health problems like liver injury and brain damage but chronic alcohol consumption can also hurt the lungs. People who regularly drink more than the daily maximum levels recommended by the Centers for Disease Control and Prevention (CDC) (1 drink per day for women or 2 drinks per day for men) are more likely to suffer from pneumonia and acute lung injuries.

The primary goal of this clinical research study is to determine if a Food and Drug Administration (FDA) approved diabetes drug, called pioglitazone, can improve the lung immune defenses in otherwise healthy alcoholics. There is strong evidence from experimental animal models that pioglitazone preserves lung health even during daily alcohol ingestion.

This National Institutes of Health (NIH) funded project will recruit veterans who are patients at the Atlanta VA Hospital. Half of the participants will be randomly assigned to receive pioglitazone and half will be assigned to receive no treatment. Participants assigned to pioglitazone will take the pill once per day for two to four weeks. To measure the effect of pioglitazone, participants will undergo a procedure called a bronchoscopy before taking the study drug and then again 2-4 weeks later to look for changes. The bronchoscopy will allow researchers to obtain fluid from the lungs to see how well their immune cells respond to bacteria (by determining phagocytic capacity). The researchers also plan to enroll 12 healthy veteran patients who do not drink. These participants will undergo a one-time bronchoscopy and no other visits will be required of them.

The findings from this study will guide future, larger scale clinical trials to determine if pioglitazone can be used in the clinical setting to improve outcomes in alcoholics who develop pneumonia or acute lung injury.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 50
• Est. completion date: January 28, 2020
• Est. primary completion date: January 28, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Active alcohol use disorder, with last alcoholic drink within 8 days of randomization (for those in the alcohol use disorder arms)

Exclusion Criteria:

• History of diabetes

• History of heart failure

• History of cirrhosis of the liver

• Elevation of liver enzymes greater than 2.5 times upper limit of normal

• History of bladder cancer

• Primary substance of abuse is something other than alcohol

• Current abnormal chest x-ray or other evidence of significant lung disease

• HIV-positive

• Renal impairment, defined as glomerular filtration rate (GFR) <60

• Current pregnancy or planning to become pregnant in the next 6 months

• Currently on pioglitazone treatment for another reason

• Contraindication to treatment with pioglitazone

• Any active and uncontrolled medical problem that may negatively impact the study results

• Currently on an oral steroid or inhaled corticosteroid

• History of profound psychiatric problems, poor compliance, or other psycho-social issues that may negatively impact participation

• Inability to give informed consent (i.e., limited cognitive capacity)

• Non-English speaking

Related Conditions & MeSH terms

• Alcoholism

Intervention

Drug:
• Pioglitazone
Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.

Locations

Country	Name	City	State
United States	Atlanta VA Medical Center	Decatur	Georgia

Sponsors (2)

Lead Sponsor	Collaborator
Emory University	National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in phagocytic index	The change in phagocytic index will be determined between the alcohol use disorder study arms to examine the effect of PIO treatment. Phagocytic index of the alveolar macrophage is the rate at which particles are cleared from a culture. The phagocytic index is a well-established marker of immune function and its improvement with pioglitazone (PIO) treatment would indicate reversal of the alcoholic lung phenotype. The phagocytic index will be measured in bronchoalveolar lavage (BAL) fluids.	Baseline, After 2-4 weeks
Secondary	Change in nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase)	The change in nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) will be determined between the alcohol use disorder study arms to examine the effect of PIO treatment. Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) is an enzyme complex. NADPH oxidases are the primary sources of oxidative stress in the alveolar macrophage. Chronic alcohol consumption causes pulmonary oxidative stress via increased expression and activity of NADPH oxidases. NADPH oxidases will be measured in bronchoalveolar lavage (BAL) fluids.	Baseline, After 2-4 weeks
Secondary	Change in alveolar macrophage oxidative stress	The change in alveolar macrophage oxidative stress will be determined between the alcohol use disorder study arms to examine the effect of PIO treatment. The alveolar macrophage plays a crucial role in lung immunity by protecting the individual from developing respiratory infections such as pneumonia. Alcohol-induced oxidative stress impairs the ability of the alveolar macrophage to function normally. A decrease in alveolar oxidative stress with pioglitazone treatment would indicate that the treatment is having a positive impact. This outcome will be measured in bronchoalveolar lavage (BAL) fluids.	Baseline, After 2-4 weeks
Secondary	Change in redox couple glutathione/glutathione disulfide (GSH/GSSG)	The change in redox couple glutathione/glutathione disulfide (GSH/GSSG) will be determined between the alcohol use disorder study arms to examine the effect of PIO treatment. Glutathione (GSH)/glutathione disulfide (GSSG) is a redox (a chemical reaction) which is frequently measured as an indicator of oxidative stress. The antioxidant GSH reduces to GSSG and in a healthy state there is greater than 90% GSH to less than 10% GSSG. Chronic alcohol consumption causes pulmonary oxidative stress via decreased levels of GSH. GSH and GSSG will be measured in bronchoalveolar lavage (BAL) and exhaled breath condensate (EBC) fluids.	Baseline, After 2-4 weeks
Secondary	Change in cysteine/cystine (Cys/CySS) redox potential	The change in cysteine/cystine (Cys/CySS) redox potential will be determined between the alcohol use disorder study arms to examine the effect of PIO treatment. Cysteine (Cys)/cystine (CySS) is a redox (a chemical reaction) regulating a variety of biological processes. CySS is the oxidized form of Cys and the ratio is sensitive to alcohol abuse, among other environmental exposures. Cys and CySS will be measured in bronchoalveolar lavage (BAL) and exhaled breath condensate (EBC) fluids.	Baseline, After 2-4 weeks
Secondary	Comparison of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase)	Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) will be compared between the PIO treatment arm and the healthy control arm to determine if PIO treatment leads to normal function. Nicotinamide adenine dinucleotide phosphate-oxidase (NADPH oxidase) is an enzyme complex. NADPH oxidases are the primary sources of oxidative stress in the alveolar macrophage. Chronic alcohol consumption causes pulmonary oxidative stress via increased expression and activity of NADPH oxidases. NADPH oxidases will be measured in bronchoalveolar lavage (BAL) fluids.	Baseline (control group), After 2-4 weeks (treatment group)
Secondary	Comparison of alveolar macrophage oxidative stress	Alveolar macrophage oxidative stress will be compared between the PIO treatment arm and the healthy control arm to determine if PIO treatment leads to normal function. The alveolar macrophage plays a crucial role in lung immunity by protecting the individual from developing respiratory infections such as pneumonia. Alcohol-induced oxidative stress impairs the ability of the alveolar macrophage to function normally. A decrease in alveolar oxidative stress with pioglitazone treatment would indicate that the treatment is having a positive impact. This outcome will be measured in bronchoalveolar lavage (BAL) fluids.	Baseline (control group), After 2-4 weeks (treatment group)
Secondary	Comparison of redox couple glutathione/glutathione disulfide (GSH/GSSG)	Redox couple glutathione/glutathione disulfide (GSH/GSSG) will be compared between the PIO treatment arm and the healthy control arm to determine if PIO treatment leads to normal function. Glutathione (GSH)/glutathione disulfide (GSSG) is a redox (a chemical reaction) which is frequently measured as an indicator of oxidative stress. The antioxidant GSH reduces to GSSG and in a healthy state there is greater than 90% GSH to less than 10% GSSG. Chronic alcohol consumption causes pulmonary oxidative stress via decreased levels of GSH. GSH and GSSG will be measured in bronchoalveolar lavage (BAL) and exhaled breath condensate (EBC) fluids.	Baseline (control group), After 2-4 weeks (treatment group)
Secondary	Comparison of cysteine/cystine (Cys/CySS) redox potential	Cysteine/cystine (Cys/CySS) redox potential will be compared between the PIO treatment arm and the healthy control arm to determine if PIO treatment leads to normal function. Cysteine (Cys)/cystine (CySS) is a redox (a chemical reaction) regulating a variety of biological processes. CySS is the oxidized form of Cys and the ratio is sensitive to alcohol abuse, among other environmental exposures. Cys and CySS will be measured in bronchoalveolar lavage (BAL) and exhaled breath condensate (EBC) fluids.	Baseline (control group), After 2-4 weeks (treatment group)